ECELLFrance Publications

2013 - 23 publications

Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints.

Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Büscher D, Fibbe W, Foussat A, Kwa M, Lantz O, Mačiulaitis R, Palomäki T, Schneider CK, Sensebé L, Tachdjian G, Tarte K, Tosca L, Salmikangas P.
Cytotherapy, 2013, 15(7):753-9. doi: 10.1016/j.jcyt.2013.03.005

Barkholt et al. 2013.pdf

Adobe Acrobat Document 117.0 KB

Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue.

Deschaseaux F, Gaillard J, Langonné A, Chauveau C, Naji A, Bouacida A, Rosset P, Heymann D, De Pinieux G, Rouas-Freiss N, Sensébé L.

FASEB J. 2013, 27(8):2977-87. doi: 10.1096/fj.13-227264

Donor selection and release criteria of cellular therapy products.

Eichler H, Schrezenmeier H, Schallmoser K, Strunk D, Nystedt J, Kaartinen T, Korhonen M, Fleury-Cappellesso S, Sensebé L, Bönig H, Rebulla P, Giodano R, Lecchi L, Takanashi M, Watt SM, Austin EB, Guttridge M, Mc Laughlin LS, Panzer S, Reesink HW.

Vox Sang. 2013;104:67-91. doi: 10.1111/j.1423-0410.2012.01619.x.

Sox9-regulated miRNA-574-3p inhibits chondrogenic differentiation of mesenchymal stem cells.

Guérit D, Philipot D, Chuchana P, Toupet K, Brondello JM, Mathieu M, Jorgensen C and Noël D.
PLoS ONE, 2013, 23;8(4):e62582. doi: 10.1371/journal.pone.0062582.

Guérit et al. 2013.pdf

Adobe Acrobat Document 668.6 KB

Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal.

Krampera, M., Galipeau, J., Shi, Y., Tarte, K., Sensebe, L., and MSC Committee of the International Society for Cellular Therapy (ISCT)
Cytotherapy, 2013, 15(9):1054-61. doi: 10.1016/j.jcyt.2013.02.010

Krampera et al. 2013.pdf

Adobe Acrobat Document 139.6 KB

Platelet lysate coating on scaffolds directly and indirectly enhances cell migration, improving bone and blood vessel formation.

Leotot J, Coquelin L, Bodivit G, Bierling P, Hernigou P, Rouard H, Chevallier N.
Acta Biomater. 2013, 9(5):6630-40. doi: 10.1016/j.actbio.2013.02.003

Leotot et al. 2013.pdf

Adobe Acrobat Document 1.2 MB

Tissue-specific and SRSF1-dependent splicing of fibronectin, a matrix protein that controls host cell invasion.

Lopez-Mejia IC, De Toledo M, Della Seta F, Fafet P, Rebouissou C, Deleuze V, Blanchard JM, Jorgensen C, Tazi J and Vignais ML.
Mol. Biol. Cell, 2013, 24(20):3164-76. doi: 10.1091/mbc.E13-03-0142

Lopez-Meija et al. 2013.pdf

Adobe Acrobat Document 5.8 MB

Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells.

Luz-Crawford P, Kurte M, Bravo-Alegría J, Contreras R, Nova-Lamperti E, Tejedor G, Noël D, Jorgensen C, Figueroa F, Djouad F and Carrion F.
Stem Cell Res Ther, 2013, 4;4(3):65. doi: 10.1186/scrt216

Luz-Crawford et al. 2013.pdf

Adobe Acrobat Document 4.1 MB

Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.

Menard C, Pacelli L, Bassi G, Dulong J, Bifari F, Bezier I, Zanoncello J, Ricciardi M, Latour M, Bourin P, Schrezenmeier H, Sensebé L, Tarte K, Krampera M.
Stem Cells Dev, 2013, 15;22(12):1789-801. doi: 10.1089/scd.2012.0594.

Bourin et al. 2013.pdf

Adobe Acrobat Document 653.0 KB

Mesenchymal Stromal Cells: Updates and Therapeutic Outlook in Rheumatic Diseases.

Pers YM, Jorgensen C.
J Clin Med. 2013, 23;2(4):201-13. doi: 10.3390/jcm2040201

Pers et al. 2013.pdf

Adobe Acrobat Document 441.3 KB

CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by mesenchymal stem cells in human

Varin A, Pontikoglou C, Labat E, Deschaseaux F and Sensebé L.
PLoS ONE, 2013, 5;8(8):e72831. doi: 10.1371/journal.pone.0072831

Varin et al. 2013.pdf

Adobe Acrobat Document 2.3 MB

Long-term detection of human adipose-derived mesenchymal stem cells after intraarticular injection in SCID mice.

Toupet K, Maumus M, Peyrafitte JA, Bourin P, van Lent PLEM, Ferreira R, Orsetti B, Pirot N, Casteilla L, Jorgensen C and Noël D.
Arthritis Rheum, 2013, 65(7):1786-94. doi: 10.1002/art.37960

Toupet et al. 2013.pdf

Adobe Acrobat Document 487.5 KB

Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2

Manferdini C, Maumus M, Gabusi E, Piacentini A, Filardo G, Peyrafitte JA, Jorgensen C, Bourin P, Fleury-Cappellesso S, Facchini A, Noël D, Lisignoli G.
Arthritis Rhum. 2013; 65:1271-1281.

Manferdini et al. 2013.pdf

Adobe Acrobat Document 814.0 KB

Adipose mesenchymal stem cells protect chondrocytes from degeneration associated with osteoarthritis

Maumus M, Manferdini C, Toupet K, Peyrafitte JA, Ferreira R, Facchini A, Gabusi E, Bourin P, Jorgensen C, Lisignoli G and Noel D.
Stem Cell Res, 2013a, 11(2):834-44. doi: 10.1016/j.scr.2013.05.008

Maumus et al. 2013a.pdf

Adobe Acrobat Document 965.2 KB

Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes

Maumus M, Jorgensen C and Noël D.
Biochimie, 2013b, 95(12):2229-34. doi: 10.1016/j.biochi.2013.04.017

Maumus et al. 2013b.pdf

Adobe Acrobat Document 797.1 KB

Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy

Naji A, Rouas-Freiss N, Durrbach A, Carosella ED, Sensébé L and Deschaseaux F.
Stem Cells, 2013, 31(11):2296-303. doi: 10.1002/stem.1494

Naji et al. 2013.pdf

Adobe Acrobat Document 969.7 KB

Mesenchymal stromal cells: misconceptions and evolving concepts

Phinney DG and Sensebé L.
Cytotherapy, 2013, 15(2):140-5. doi: 10.1016/j.jcyt.2012.11.005

Phinney et al. 2013a.pdf

Adobe Acrobat Document 211.9 KB

MSCs: science and trials

Phinney DG, Galipeau J, Krampera M, Martin I, Shi Y and Sensebé L.
Nat. Med, 2013, 19(7):812. doi: 10.1038/nm.3220

Phinney et al. 2013b.pdf

Adobe Acrobat Document 115.2 KB

Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis

Présumey J, Courties G, Louis-Plence P, Escriou V, Scherman D, Pers YM, Yssel H, Pène J, Kyburz D, Gay S, Jorgensen C and Apparailly F.
Ann. Rheum. Dis, 2013, 72(10):1717-24. doi: 10.1136/annrheumdis-2012-202403

Présumey et al. 2013.pdf

Adobe Acrobat Document 828.2 KB

GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system

Rojewski MT, Fekete N, Baila S, Nguyen K, Fürst D, Antwiler D, Dausend J, Kreja L, Ignatius A, Sensebé L and Schrezenmeier H.
Cell Transplant, 2013, 22(11):1981-2000. doi: 10.3727/096368912X657990

Rojewski et al. 2013.pdf

Adobe Acrobat Document 800.8 KB

Beyond genetic stability of mesenchymal stromal cells

Sensebé L.
Cytotherapy, 2013, 15(11):1307-8. doi: 10.1016/j.jcyt.2013.09.001

Sensebé 2013a.pdf

Adobe Acrobat Document 68.3 KB

Biodistribution of mesenchymal stem/stromal cells in a preclinical setting

Sensebé L and Fleury-Cappellesso S.
Stem Cells Int, 2013, 2013:678063. doi: 10.1155/2013/678063

Sensebé et al. 2013b.pdf

Adobe Acrobat Document 482.0 KB

Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review

Sensebé L, Gadelorge M and Fleury-Cappellesso S.
Stem Cell Res Ther, 2013, 7;4(3):66. doi: 10.1186/scrt217

Sensebé et al. 2013c.pdf

Adobe Acrobat Document 213.5 KB